Ajanta Pharma share buyback record date set for today. Key details in 5 points
Ajanta Pharma share buyback has been announced at 1,425 per share24-03-2023
24-03-2023
Ajanta Pharma Buyback: Should you tender the stock?
Possible single digit returns to consider before tendering stock. March 24 is the record date22-03-2023
AJANTA PHARMA LTD. - 532331 - Announcement under Regulation 30 (LODR)-Public Announcement-Buyback of Shares
This is in furtherance to our intimation dated March 10, 2023 informing the stock exchanges w.r.t. Buy-back of 22,10,500 shares of the Company at a price of ? 1,425/- per equity share, on a proportionate basis, through the tender offer process ('Buyback'), in accordance with the provisions of the Companies Act, 2013, and rules made thereunder, and the Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018 (the 'SEBI Buyback Regulations') as amended from time to time and other applicable laws. In this regard, please find enclosed: (a) A copy of the Public Announcement, as published in newspapers; and (b) Certified true copy of the resolution passed by the Board of Directors on dated March 10 2023 for approving the proposal of Buyback. You are requested to kindly take the same on record.14-03-2023
Buy Ajanta Pharma; target of Rs 1410: Motilal Oswal
Motilal Oswal is bullish on Ajanta Pharma recommended buy rating on the stock with a target price of Rs 1410 in its research report dated March 10, 2023.13-03-2023
AJANTA PHARMA LTD. - 532331 - Declaration Of Voting Results Of Postal Ballot Under Regulation 44 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015
We refer to our letter dated 7th February 2023, vide which we had submitted the Postal Ballot Notice dated 1st February 2023, sent to the members of the Company for seeking their approval by way of Ordinary Resolution through Remote E-voting for re-appointment & remuneration of Mr. Yogesh M. Agrawal as Managing Director and Mr. Rajesh M. Agrawal as Joint Managing Director respectively. Post-closing of e-voting period at 17:00 hours (IST) on 9th March 2023, the Scrutinizer has submitted his Report on the Results of the Postal Ballot (through remote e-voting) on 10th March 2023. As per the Report, the said Resolutions have been passed by the Members of the Company with requisite majority. Pursuant to Regulation 44(3) of the Listing Regulations, please find enclosed herewith the voting results and the Scrutinizer''s Report thereon dated 10th March 2023.10-03-2023
Ajanta Pharma share buyback announced. Price, record date, key details to know
Ajanta Pharma shares were trading more than a per cent lower at 1,213 apiece on the BSE in afternoon deals10-03-2023
AJANTA PHARMA LTD. - 532331 - Intimation With Respect To Fixing Of Record Date In Relation To The Proposed Buyback Under Regulation 42 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
We wish to inform you that in accordance with Regulation 42 of the Listing Regulations and Regulation 9(i) of the SEBI (Buy-Back of Securities) Regulations, 2018, as amended, the Buyback Committee of the Company, being duly authorised by the Board of Directors of the Company in this regard, have at their meeting held on March 10, 2023, considered and approved the record date for the proposed Buy-back offer as Friday, March 24, 2023.10-03-2023
AJANTA PHARMA LTD. - 532331 - Board Meeting Outcome for Approving Buyback Of Equity Shares
The Board of Directors of the Company, at its meeting held today, i.e., March 10, 2023, has inter-alia considered and approved Buyback of 22,10,500 fully paid-up Equity Shares of face value of ? 2/- each by the Company (representing 2.59% of the total number of Equity Shares of the Company as of March 31, 2022 (not adjusted for bonus issue undertaken by Company as on June 24, 2022 ) at a price of ? 1,425/- (Indian Rupees One Thousand Four Hundred Twenty Five only) per Equity Share payable in cash for a total consideration not exceeding ? 315 crores (Indian Rupees Three Hundred and Fifteen crores only) (excluding transaction costs such as fees, brokerage, taxes, duties, etc.), which represents 9.93% and 9.64% of the aggregate of the Company's paid-up capital and free reserves as per the standalone and consolidated audited financials of the Company for the year ended as on March 31, 2022 respectively.10-03-2023
Ajanta Pharma edges higher on news of likely share buyback
If approved, this will mark the company's third buyback of equity shares.08-03-2023
Ajanta Pharma Board to consider buyback of shares on 10 March
Ajanta Pharma said the trading window for dealing in securities of the firm will remain closed up to 48 hours after the conclusion of the board meeting scheduled to be held on Friday06-03-2023